AYAA OUZA: Open Payments
NPI 1922662501 · HAMTRAMCK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$714 in 32 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $714
Food & beverage: $714
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $263 |
| ABBVIE INC. | 5 | $117 |
| Neurocrine BioSciences, Inc. | 2 | $71 |
| Supernus Pharmaceuticals, Inc. | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Alkermes, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Gilead Sciences, Inc. | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, Qelbree, Auvelity, REXULTI, ARISTADA, TRINTELLIX.
Industry payments across MI — which companies pay providers there.
